International Journal of Molecular Sciences
Cure8 research brief
Why This Matters
The study identifies berberine as a compound that reduced epithelial pyroptosis and improved disease markers in a mouse model of bacterial colitis, suggesting a possible new mechanism-target for colitis therapies. This is preclinical evidence that may guide future research but is not proof of benefit in humans.
Who Should Pay Attention
Researchers, preclinical drug developers, clinicians interested in mechanisms of epithelial cell death and barrier function, and patients following supplements or traditional remedies (with caution).
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
A lab and mouse study in the International Journal of Molecular Sciences tested berberine (an alkaloid from Coptis chinensis) in cell models and a Citrobacter rodentium-induced colitis model.
The authors report that berberine reduced epithelial cell death and markers of GSDME-mediated pyroptosis in cultured epithelial cells and lowered colonic GSDME cleavage, improved barrier markers (Tjp1, Muc2), and reduced weight loss, diarrhea, colon shortening, and histopathology in infected mice, without lowering bacterial load in this experiment.
These results come from cellular assays and an experimental infectious-colitis mouse model, not human trials. The paper suggests a possible mechanism (modulation of GSDME and reduced pyroptosis) and positions berberine as a candidate for further study in infection-associated colitis.
If you follow berberine as a supplement or traditional remedy, note that this study does not provide evidence that it is safe or effective for people with IBD; clinical studies in humans would be needed. Discuss any supplements with your gastroenterology team before starting them.
Keep In Mind
Preclinical cell and mouse study—results may not apply to humans. Not a clinical trial; safety and efficacy in people with IBD are untested here.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternational Journal of Molecular Sciences
PublisherMDPI AG
AuthorsMeiqi Zhang, Sixian Wei, Zheng Lou +8 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 29, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Beijing Nova Program of Science and Technology, award 20240484706; award 20240484706; National Natural Science Foundation of China, award 82530125; award 82530125; Beijing Natural Science Foundation, award 7242239
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Anti-inflammatory efficacy of diosgenin in an oxazolone-induced model of ulcerative colitis in mice via suppression of Th2 pathways and pSTAT3 expression: A prospective study.
A natural compound (diosgenin) reduced disease signs and inflammatory markers in a mouse model of ulcerative colitis, suggesting a possible anti-inflammatory mechanism that could inform future preclinical research.
MIT-001, a Mitochondria-Targeted ROS Scavenger, Ameliorates DSS-Induced Colitis and Is Associated with Reduced HMGB1 and IL-1β Expression.
The study presents a mitochondria-targeted compound that reduced necrosis markers, HMGB1, and IL-1β in cell and mouse colitis models, highlighting a potential new pathway for IBD treatment research.
SR9009 regulates macrophage polarization via the NR1D1/NF-κB axis to ameliorate obesity-associated ulcerative colitis
This study identifies NR1D1 activation by the experimental drug SR9009 as a potential way to reduce inflammation and improve colon pathology in a mouse model of obesity-associated ulcerative colitis.